title: LAPTM4B polymorphism increases susceptibility to multiple cancers in Chinese populations: a meta-analysis.
abstract: BACKGROUND
  Lysosome-associated protein transmembrane-4 beta (LAPTM4B) is a novel cancer-related gene. While recent studies have reported that the LAPTM4B polymorphism increased the susceptibility of several cancers, the results remain inconclusive. Therefore, we performed a meta-analysis to systematically summarize the possible association.
  
  
  RESULTS
  The meta-analysis was conducted based on 17 studies in Chinese populations, including 4160 cases and 4148 controls. The relevant studies were searched through electronic databases updated in November 2013. The strength of association between the LAPTM4B polymorphism and susceptibility to multiple cancers was assessed by odds ratio (OR) and 95% confidence interval (95% CI).The meta-analysis results suggested that the LAPTM4B polymorphism was significantly associated with overall susceptibility to multiple cancers in all genetic models (*2 vs. *1, OR = 1.53, 95% CI = 1.37-1.70; *2/2 vs. *1/1, OR = 2.18, 95% CI = 1.72-2.75; *2/1 vs.*1/1, OR = 1.62, 95% CI = 1.41-1.86; *2/1 + *2/2 vs. *1/1, OR = 1.70, 95% CI = 1.47-1.97; *2/2 vs. *2/1 + *1/1, OR = 1.76, 95% CI = 1.50-2.05). Further subgroup analysis revealed a significant association between the LAPTM4B polymorphism and cancer susceptibility in the subgroups stratified by control source, cancer type, histopathologic differentiation, and TNM stage.
  
  
  CONCLUSIONS
  This meta-analysis indicated that the LAPTM4B *2 allele was associated with increasing risk of multiple cancers, tumor initiation and development.
authors.forename: Cuiju
authors.initials: C
authors.lastname: Mo
authors.forename: Yu
authors.initials: Y
authors.lastname: Lu
authors.forename: Yan
authors.initials: Y
authors.lastname: Deng
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.forename: Taijie
authors.initials: T
authors.lastname: Li
authors.forename: Yu
authors.initials: Y
authors.lastname: He
authors.forename: Qiliu
authors.initials: Q
authors.lastname: Peng
authors.forename: Xue
authors.initials: X
authors.lastname: Qin
authors.affiliation: Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China. lis8858@126.com.
authors.forename: Shan
authors.initials: S
authors.lastname: Li
mesh_terms: D044466:Asian People / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics*; D009369:Neoplasms / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic
chemical_list: C477083:LAPTM4B protein, human; D008565:Membrane Proteins; D015513:Oncogene Proteins
references.citation: Beijing Da Xue Xue Bao Yi Xue Ban. 2003 Aug;35(4):340-7
references.pmid: 12947545
references.citation: Cancer. 2011 Feb 1;117(3):440-5
references.pmid: 20862743
references.citation: Chin Med J (Engl). 2000 Oct;113(10):881-5
references.pmid: 11775832
references.citation: Ann Oncol. 2007 Feb;18(2):311-6
references.pmid: 17074969
references.citation: Med Oncol. 2012 Dec;29(4):2809-13
references.pmid: 22302286
references.citation: Oncogene. 2003 Aug 7;22(32):5060-9
references.pmid: 12902989
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Cancer Sci. 2009 Dec;100(12):2335-40
references.pmid: 19843073
references.citation: Ann Oncol. 2012 Jul;23(7):1864-9
references.pmid: 22156622
references.citation: Ann Oncol. 2008 Mar;19(3):527-32
references.pmid: 17965115
references.citation: Cancer Lett. 2005 Jun 16;224(1):93-103
references.pmid: 15911104
references.citation: Zhongguo Fei Ai Za Zhi. 2006 Apr 20;9(2):109-12
references.pmid: 21144292
references.citation: Nat Med. 2010 Feb;16(2):214-8
references.pmid: 20098429
references.citation: Hepatogastroenterology. 2010 Mar-Apr;57(98):207-11
references.pmid: 20583413
references.citation: Beijing Da Xue Xue Bao Yi Xue Ban. 2003 Aug;35(4):348-52
references.pmid: 12947546
references.citation: Cancer. 2011 Jun 15;117(12):2652-8
references.pmid: 21656743
references.citation: Am J Surg. 2010 Apr;199(4):515-21
references.pmid: 19954766
references.citation: Biomarkers. 2013 Mar;18(2):136-43
references.pmid: 23312008
references.citation: Oncogene. 2010 Oct 28;29(43):5785-95
references.pmid: 20711237
references.citation: PLoS One. 2012;7(9):e44916
references.pmid: 22984585
references.citation: PLoS One. 2012;7(9):e45290
references.pmid: 22984631
references.citation: Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Jun 18;37(3):302-5
references.pmid: 15968325
references.citation: Jpn J Clin Oncol. 2012 May;42(5):413-9
references.pmid: 22412199
references.citation: Med Oncol. 2013 Mar;30(1):470
references.pmid: 23345117
references.citation: J Int Med Res. 2012;40(4):1275-83
references.pmid: 22971479
references.citation: Nat Genet. 2003 Feb;33(2):177-82
references.pmid: 12524541
references.citation: World J Gastroenterol. 2005 May 14;11(18):2704-8
references.pmid: 15884107
references.citation: Med Oncol. 2012 Dec;29(4):2744-9
references.pmid: 22207410
references.citation: PLoS One. 2012;7(4):e34984
references.pmid: 22509374
references.citation: Cancer Epidemiol. 2012 Aug;36(4):364-8
references.pmid: 22270081